Methenamine hippurate for preventing urinary tract infections

Area of Science:

• Urology
• Infectious Diseases
• Pharmacology

Background:

• Methenamine salts are commonly prescribed for preventing urinary tract infections (UTIs).
• Assessing the efficacy of methenamine hippurate in UTI prevention is crucial for clinical practice.

Purpose of the Study:

• To evaluate the effectiveness of methenamine hippurate in preventing UTIs through a systematic review of randomized controlled trials.

Main Methods:

• Comprehensive literature search across multiple databases (Cochrane, MEDLINE, EMBASE, etc.) and contact with manufacturers for unpublished data.
• Inclusion of randomized and quasi-randomized trials comparing methenamine hippurate against a control group for UTI prevention across all populations.
• Independent data extraction and assessment by two reviewers, with discrepancies resolved by senior researchers, followed by descriptive analysis and meta-analyses where appropriate.

Main Results:

• Eleven studies met the inclusion criteria; seven were included in meta-analyses, but heterogeneity limited pooled estimate interpretation.
• Poor overall trial quality was noted. Some trials suggested a favorable treatment effect, but heterogeneity prevented definitive conclusions.
• One study indicated potential efficacy in patients without upper renal tract abnormalities, but this requires cautious interpretation due to small sample sizes and methodological issues.

Conclusions:

• Current evidence is insufficient to definitively support methenamine hippurate for urinary prophylaxis.
• Hypothesis generated: methenamine hippurate may be effective in patients without known upper renal tract abnormalities.
• Low reported adverse event rates suggest minimal harm, but cautious interpretation of efficacy data is warranted due to study limitations.